Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the fourth quarter…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks